Co-Diagnostics, Inc. earnings releases CODX

Co-Diagnostics, Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $166,131 (+2.0% year over year) and diluted EPS of -$1.46. It usually reports 44–69 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–69 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 13, 2026
44 days after quarter end
Q2 FY2026
ended Jun 30, 2026
0
+2.0%
-6
+18.7%
-1.46
+79.1%
May 14, 2026
44 days after quarter end
Q1 FY2026
ended Mar 31, 2026
0
+190.3%
-9
-21.3%
-4.06
+42.4%
Mar 10, 2026
69 days after quarter end
Q4 FY2025
ended Dec 31, 2025
0
+76.7%
-26
-133.4%
0.27
+107.0%
Nov 13, 2025
44 days after quarter end
Q3 FY2025
ended Sep 30, 2025
0
-77.3%
-6
+39.3%
-0.16
+50.0%
Aug 14, 2025
45 days after quarter end
Q2 FY2025
ended Jun 30, 2025
0
-93.9%
-8
-1.7%
-7.00
-2700.0%
May 8, 2025
38 days after quarter end
Q1 FY2025
ended Mar 31, 2025
0
-89.3%
-8
+19.1%
-7.05
-2174.2%
Nov 7, 2024
38 days after quarter end
Q3 FY2024
ended Sep 30, 2024
1
-73.9%
-10
-62.1%
-0.32
-60.0%
Aug 8, 2024
39 days after quarter end
—
ended Jun 30, 2024
—
—
—

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
CODX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
UT
Headquarters
Salt Lake City, UT
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1692415

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.